The FDA has approved adalimumab (Humira®, Abbott) for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis (PsA).
PsA is a chronic autoimmune disease that combines the symptoms of arthritis (joint pain and inflammation) with those of psoriatic skin disease (dry, scaly skin). It is the first new disease indication for this agent since its approval for rheumatoid arthritis (RA).
This approval is based on results of the Adalimumab Effectiveness in Psori-atic Arthritis Trial (ADEPT). At 24 weeks, treated patients improved in both joint and skin disease symptoms more than placebo patients did. buy zetia
The recommended dose for PsA is 40 mg every other week by subcutaneous injection.
Abbott received European approval for PsA and early severe RA on August 8, 2005.